Pentoxifylline-d3

Pentoxifylline-d3 (BL-191-d3) is deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

Product Specifications

CAS Number

[1185878-97-0]

Product Name Alternative

BL-191-d3; PTX-d3; Oxpentifylline-d3

UNSPSC

12352005

Target

Autophagy; HIV; Isotope-Labeled Compounds; Phosphodiesterase (PDE)

Related Pathways

Anti-infection; Autophagy; Metabolic Enzyme/Protease; Others

Applications

Cancer-programmed cell death

Field of Research

Cardiovascular Disease; Cancer

Smiles

O=C1C2=C(N=CN2C([2H])([2H])[2H])N(C(N1CCCCC(C)=O)=O)C

Molecular Formula

C13H15D3N4O3

Molecular Weight

281.33

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Iffat Hassan, et al. Pentoxifylline and its applications in dermatology. Indian Dermatol Online J. 2014 Oct-Dec; 5 (4) : 510–516.|[3]A Ward, et al. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987 Jul;34 (1) :50-97.|[4]Yessica Cristina Castellanos-Esparza, et al. Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells. Int J Oncol. 2018 Apr;52 (4) :1246-1254.|[5]Shabnam Movassaghi, et al. Effect of Pentoxifylline on Ischemia- induced Brain Damage and Spatial Memory Impairment in Rat. Iran J Basic Med Sci. 2012 Sep-Oct; 15 (5) : 1083-1090.